MA44864A - Trithérapie pour le traitement d'une maladie intestinale inflammatoire - Google Patents

Trithérapie pour le traitement d'une maladie intestinale inflammatoire

Info

Publication number
MA44864A
MA44864A MA044864A MA44864A MA44864A MA 44864 A MA44864 A MA 44864A MA 044864 A MA044864 A MA 044864A MA 44864 A MA44864 A MA 44864A MA 44864 A MA44864 A MA 44864A
Authority
MA
Morocco
Prior art keywords
tritherapy
treatment
intestinal disease
inflammatory intestinal
inflammatory
Prior art date
Application number
MA044864A
Other languages
English (en)
Inventor
Jean-Frederic Colombel
Trevor Warren Lissoos
Original Assignee
Icahn School Med Mount Sinai
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School Med Mount Sinai, Millennium Pharm Inc filed Critical Icahn School Med Mount Sinai
Publication of MA44864A publication Critical patent/MA44864A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA044864A 2016-05-04 2017-05-04 Trithérapie pour le traitement d'une maladie intestinale inflammatoire MA44864A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662331813P 2016-05-04 2016-05-04

Publications (1)

Publication Number Publication Date
MA44864A true MA44864A (fr) 2019-03-13

Family

ID=58710089

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044864A MA44864A (fr) 2016-05-04 2017-05-04 Trithérapie pour le traitement d'une maladie intestinale inflammatoire

Country Status (5)

Country Link
US (2) US10918716B2 (fr)
EP (1) EP3452070A1 (fr)
JP (2) JP7162533B2 (fr)
MA (1) MA44864A (fr)
WO (1) WO2017192867A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
US20170327584A1 (en) 2014-11-26 2017-11-16 Millennium Pharmaceuticals, Inc. Vedolizumab for the Treatment of Fistulizing Crohn's Disease
MA45245A (fr) 2016-06-12 2019-04-17 Millennium Pharm Inc Méthode de traitement de maladie intestinale inflammatoire
EP4068295A1 (fr) * 2021-03-29 2022-10-05 Siemens Healthcare GmbH Système de support de décision clinique d'estimation de l'optimisation de traitements liés aux médicaments concernant des maladies inflammatoires
US20240254243A1 (en) * 2021-06-17 2024-08-01 Prometheus Laboratories Inc. Systems and methods for improved targeted therapy
CN113402583B (zh) * 2021-06-19 2023-03-21 江西农业大学 Qgk三肽及其应用
CN114225025B (zh) * 2021-12-29 2022-07-26 贵州酵德生物科技有限公司 含有益生菌的制剂在治疗肠胃疾病中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69637155T2 (de) 1995-02-10 2008-02-07 Millennium Pharmaceuticals, Inc., Cambridge Addressine der schleimhaut und der blutgefässe und ihre verwendung
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US20010046496A1 (en) 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
AU2006316629A1 (en) 2005-11-17 2007-05-31 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with alpha 4 beta 7 integrin
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
TWI723339B (zh) 2011-05-02 2021-04-01 美商千禧製藥公司 抗-α4β7抗體之調配物
US20170327584A1 (en) 2014-11-26 2017-11-16 Millennium Pharmaceuticals, Inc. Vedolizumab for the Treatment of Fistulizing Crohn's Disease
WO2016105572A1 (fr) 2014-12-24 2016-06-30 Millennium Pharmaceuticals, Inc. Prévision du résultat de traitement avec un anticorps dirigé contre l'intégrine anti-α4β7

Also Published As

Publication number Publication date
JP7474287B2 (ja) 2024-04-24
JP2022141713A (ja) 2022-09-29
JP7162533B2 (ja) 2022-10-28
US20190142938A1 (en) 2019-05-16
US20210252141A1 (en) 2021-08-19
EP3452070A1 (fr) 2019-03-13
JP2019514974A (ja) 2019-06-06
US10918716B2 (en) 2021-02-16
WO2017192867A1 (fr) 2017-11-09

Similar Documents

Publication Publication Date Title
MA49144A (fr) Polythérapies pour le traitement du cancer
MA44864A (fr) Trithérapie pour le traitement d'une maladie intestinale inflammatoire
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d'infections virales
MA43746A (fr) Dérivés de 2-cyanoisoindoline pour le traitement du cancer
MA53661A (fr) Agonistes du récepteur farnésoïde x pour le traitement d'une maladie
MA55697A (fr) Molécules d'anticorps pour le traitement du cancer
MA45192A (fr) Traitement d'association
MA45052A (fr) Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille
MA45146A (fr) Dérivés de pyrazolopyridine pour le traitement du cancer
MA44083A (fr) Composés de biarylmonobactame pour le traitement d'infections bactériennes
FR3046933B1 (fr) Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
MA55629A (fr) Compositions d'anticorps pour le traitement de tumeurs
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
MA50409A (fr) Polythérapies pour le traitement du cancer
MA47719A (fr) Esketamine pour le traitement de la dépression
MA48637A (fr) Polythérapies pour le traitement du cancer
MA41449A (fr) Polythérapies pour le traitement de cancers
MA49906A (fr) Acides aminés à chaîne ramifiée pour le traitement d'une maladie du foie
MA51139A (fr) Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer
MA41052A (fr) Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
MA54925A (fr) Compositions pour le traitement de troubles acido-basiques
MA50391A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de troubles inflammatoires
MA47395A (fr) Méthode pour le traitement d'une maladie neurologique
MA49131A (fr) Utilisation d'antagonistes de klk5 pour le traitement d'une maladie
MA54544A (fr) Inhibiteurs de la voie jak1 pour le traitement d'une maladie gastro-intestinale